Unknown

Dataset Information

0

Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV.


ABSTRACT: Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor Usp18 in CD169+ macrophages is one important factor modulating the anti-Ebola virus immune response. The absence of Usp18 in CD169+ macrophages led to the reduced local replication of VSV-EBOV followed by a diminished innate as well as adaptive immune response. In line, CD169-Cre+/ki x Usp18fl/fl mice showed reduced innate and adaptive immune responses against the VSV wildtype strain and died quickly after infection, suggesting that a lack of Usp18 makes mice more susceptible to the side effects of the VSV vector. In conclusion, our study shows that Usp18 expression in CD169+ macrophages is one important surrogate marker for effective vaccination against VSV-EBOV, and probably other VSV-based vaccines also.

SUBMITTER: Friedrich SK 

PROVIDER: S-EPMC7157200 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>Usp18</i> Expression in CD169<sup>+</sup> Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV.

Friedrich Sarah-Kim SK   Schmitz Rosa R   Bergerhausen Michael M   Lang Judith J   Cham Lamin B LB   Duhan Vikas V   Häussinger Dieter D   Hardt Cornelia C   Addo Marylyn M   Prinz Marco M   Asano Kenichi K   Lang Philipp Alexander PA   Lang Karl Sebastian KS  

Vaccines 20200323 1


Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown. Here, using the clinically available VSV-EBOV vaccine (Ervebo), we show that the cell-intrinsic expression of the interferon-inhibitor <i>Usp18</i> in CD169<sup>+</sup> macrophages is o  ...[more]

Similar Datasets

| S-EPMC6538780 | biostudies-literature
| S-EPMC6945200 | biostudies-literature
| S-EPMC6428728 | biostudies-literature
| S-EPMC6350948 | biostudies-literature
| S-EPMC5969998 | biostudies-literature
| S-EPMC10651186 | biostudies-literature
| S-EPMC1868545 | biostudies-literature
| S-EPMC10498809 | biostudies-literature
| S-EPMC3378521 | biostudies-literature
| S-EPMC7760819 | biostudies-literature